Pandion Therapeutics Highlights Prospective of Modular Biologics Pipeline for the Cure of Autoimmune Illnesses at FOCIS 2020

WATERTOWN, Mass., Oct. 28, 2020 (Globe NEWSWIRE) — Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology corporation building novel therapeutics developed to handle the unmet requirements of clients dwelling with autoimmune health conditions, now introduced the presentation of preclinical knowledge highlighting the probable of its modular biologics pipeline for the procedure of autoimmune conditions at the Federation of Scientific Immunology Societies (FOCIS) 2020 digital once-a-year conference.

Pandion utilizes its TALON (Therapeutic Autoimmune reguLatOry proteiN) drug design and discovery platform to make antibody-dependent candidates that focus on acknowledged manage nodes in the immune process. These drug candidates are modularly engineered to either function systemically or to be focused to certain tissues via tethering modules, likely enabling a precision drugs strategy to managing autoimmune conditions. The posters presented at FOCIS confirmed in vivo proof of principle for gut- and pores and skin-tethered immune effectors, the potential wide biological results of PD-1 agonism, as nicely as an introduction to Pandion’s emerging kidney research software.

“A latest evolution in our understanding of the immune program has authorized our team to solution the remedy of autoimmune diseases in a basically new way, so that we can activate the regulation of the immune response alternatively than shutting it down wholly. We feel this knowledge could result in our potential to create for a longer period-lasting and differentiated therapies for those living with autoimmune disorders,” reported Jo Viney, Ph.D., Chief Scientific Officer and Co-Founder of Pandion Therapeutics. “The details introduced at FOCIS underscore our enthusiasm for this solution, demonstrating localized regulation of autoimmunity in animal models of graft as opposed to host ailment and vitiligo.”

The FOCIS poster displays are offered on Pandion’s web page at https://pandiontx.com/our-science/posters-displays/.

Important conclusions presented at FOCIS:

Title: A MAdCAM-tethered PD-1 Agonist Inhibits T Cell Activation and Ameliorates Intestinal Swelling
Authors: L.J. Edwards, B. Larkin, S. Alioto, D. Cluckey, D.C. Rios, E. Lurier, P. Halvey, K. Kis-Toth, N. Higginson-Scott, J.L. Viney and K.L. Otipoby
History: PD-1 is a critical immune regulator identified on activated standard T cells. Inhibition of PD1 in the procedure of cancer can result in autoimmune health conditions, including colitis. In contrast, activating, or agonizing, PD-1 success in the attenuation of overactive T cells, giving a new possible cure solution for autoimmune conditions. Pandion has designed PT001, a PD-1 agonist tethered to the intestine-selective molecule, MAdCAM.
Conclusions:

PT001 shown tethered agonism of PD-1 without the need of blocking the normal receptor and ligand interaction of either MAdCAM or PD-1.
In an animal model of graft as opposed to host illness, PT001 cure resulted in prolonged survival beyond the dosing interval.
In an animal product of graft vs . host illness, PT001 procedure lowered standard T mobile infiltration of the colon, demonstrating localized outcome of the tethered molecule.

Title: Localized Immunomodulation of T cells for Cure of Autoimmune and Inflammatory Skin Diseases
Authors: P. Mande, D. Rios, S. Borthakur, A. Boisvert, M. Rowe, P. Halvey, J.L. Viney, K. Kis-Toth, I. Mascanfroni, N. Higginson-Scott and K.L. Otipoby
Track record: Pathogenic T cells are observed in the the vast majority of continual immune-mediated pores and skin diseases. Pandion has made PD-1 agonists, which includes a pores and skin-tethered edition, intended to regulate and attenuate the activity of pathogenic T cells. In addition, Pandion has developed skin-tethered CD39 effector modules created to change a proinflammatory atmosphere to an anti-inflammatory setting. Pandion is at this time evaluating these candidates in a variety of versions of pores and skin autoimmune health conditions.
Findings:

Pores and skin-tethered effectors localized to the pores and skin.
In an animal model of vitiligo, the skin-tethered PD-1 agonist lowered pores and skin depigmentation and reduced pores and skin-certain standard T cells with no systemic consequences on T cells.
In an animal product of get in touch with hypersensitivity, the skin-tethered CD39 noticeably inhibited ear irritation.
All of the observed effects were tether-dependent, exhibiting the localized result of the tethered molecules.

Title: Generation of Kidney-Targeted IL-2 Mutein for Prevention of Graft Rejection in Renal Transplantation
Authors: B. Li, B. Larkin, T. Kiprono, M. Rowe, J. Visweswaraiah, N. Willardsen, J. Allen, K.L. Otipoby, J.L. Viney, H.H. Shaheen and N. Higginson-Scott
Background: Kidney transplant can be a existence-preserving treatment for several individuals with stop-stage renal ailment, but current extensive-term treatment plans to reduce rejection of the donor kidney can have serious aspect results.
Findings:

Pandion has established a kidney-tethered IL-2 mutein, which selectively binds to kidney tubular epithelium in vivo. Operate is ongoing understand the likely of this tethered molecule to grow regulatory T cells in the kidney as an strategy for the treatment of kidney inflammation.

Title: Molecular Profiling Reveals Anti-PD-1 Agonist Antibody-Induced Improvements to Important Immune Pathways
Authors: P.J. Halvey, E.B. Lurier, M. Cianci, J.L. Viney, K.L. Otipoby and K. Kis-Toth
History: PD-1 is a vital immune regulator observed on activated typical T cells. Inhibition of PD1 in the remedy of most cancers can final result in autoimmune conditions, which include colitis. Activating, or agonizing, PD-1, results in the inhibition of the regular T cells, and affords a possible treatment method tactic for autoimmune diseases. Pandion has made PT001, a gut-tethered PD-1 agonist, and PT627, a systemic PD-1 agonist. PD-1 agonism is a promising treatment strategy for autoimmune illnesses.
Findings:

In mobile-based mostly assays, PD-1 agonism with PT001 and PT627 resulted in the suppression of numerous known immune activation pathways, like Th1/Th2 and Th17 differentiation and chemokine signalling.

About Pandion Therapeutics
Pandion Therapeutics is establishing novel therapeutics developed to deal with the unmet needs of patients residing with autoimmune ailments. Pandion’s TALON (Therapeutic Autoimmune reguLatOry proteiN) drug layout and discovery platform permits the enterprise to make a pipeline of item candidates utilizing immunomodulatory effector modules, with the means to also blend an effector module with a tissue-focused tether module in a bifunctional structure. Pandion’s direct solution prospect PT101, a mixture of an interleukin-2 mutein effector module with a protein backbone, is made to selectively expand regulatory T cells systemically, without having activating proinflammatory cells, these as typical T cells and purely natural killer cells, is currently in a Period 1a medical trial. Pandion is continuing to build and expand its library of effector and tether modules as section of its previously-stage study and discovery pipeline. For far more facts, you should visit www.pandiontx.com.

Ahead-Seeking Statements
This press launch includes “forward-seeking statements” inside of the which means of the Private Securities Litigation Reform Act of 1995 that include significant threats and uncertainties. All statements, other than statements of historic points, contained in this press release, together with statements about the Company’s approach and clinical enhancement ideas, timelines and prospective clients, are ahead-on the lookout statements. The words and phrases “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and equivalent expressions are meant to discover ahead-on the lookout statements, despite the fact that not all forward-seeking statements incorporate these determining words and phrases. Any forward-wanting statements are dependent on management’s present expectations of foreseeable future functions and are issue to a range of risks and uncertainties that could lead to real benefits to differ materially and adversely from people set forth in, or implied by, this sort of forward-hunting statements. These pitfalls and uncertainties involve, but are not limited to, challenges connected with Pandion’s skill to get hold of and manage needed approvals from the Food and drug administration and other regulatory authorities initiate preclinical research and medical trials of PT101 and its other merchandise candidates advance PT101 and its other product candidates in preclinical exploration and clinical trials replicate in clinical trials optimistic effects observed in preclinical scientific studies progress the advancement of its products candidates under the timelines it anticipates in recent and long run medical trials acquire, retain or guard intellectual home legal rights related to its item candidates manage costs and increase the significant additional capital wanted to attain its organization targets. For a dialogue of other challenges and uncertainties, and other critical components, any of which could cause the Company’s actual outcomes to vary from these contained in the forward-seeking statements, see the “Risk Factors” segment, as properly as discussions of likely hazards, uncertainties and other essential factors, in the Company’s most recent filings with the Securities and Trade Commission. In addition, the forward-hunting statements bundled in this press launch depict the Company’s sights as of the day hereof and really should not be relied upon as symbolizing the Company’s views as of any day subsequent to the day hereof. The Enterprise anticipates that subsequent activities and developments will trigger the Company’s sights to transform. Nevertheless, though the Company may perhaps elect to update these ahead-looking statements at some point in the foreseeable future, the Organization particularly disclaims any obligation to do so.

Contacts

Media:
Kathryn Morris
The Yates Community
914-204-6412
[email protected]

Traders:
Michelle Avery
Pandion Therapeutics
857-273-0444
[email protected]